A CRISPR/Cas9 gene editing strategy has been remarkable in excising segments of integrated HIV-1 DNA sequences from the genome of latently infected human cell lines and by introducing InDel mutations, suppressing HIV-1 replication in patient-derived CD4+ T-cells, ex vivo. Here, we employed a short version of the Cas9 endonuclease, saCas9, together with a multiplex of guide RNAs (gRNAs) for targeting the viral DNA sequences within the 5′-LTR and the Gag gene for removing critically important segments of the viral DNA in transgenic mice and rats encompassing the HIV-1 genome. Tail-vein injection of transgenic mice with a recombinant Adeno-associated virus 9 (rAAV 9 ) vector expressing saCas9 and the gRNAs, rAAV:saCas9/gRNA, resulted in the cleavage of integrated HIV-1 DNA and excision of a 978 bp DNA fragment spanning between the LTR and Gag gene in the spleen, liver, heart, lung and kidney as well as in the circulating lymphocytes. Retro-orbital inoculation of rAAV 9 :saCas9/gRNA in transgenic rats eliminated a targeted segment of viral DNA and substantially decreased the level of viral gene expression in circulating blood lymphocytes. The results from the proof-of-concept studies, for the first time, demonstrate the in vivo eradication of HIV-1 DNA by CRISPR/Cas9 on delivery by an rAAV 9 vector in a range of cells and tissues that harbor integrated copies of viral DNA.
INTRODUCTION
HIV/AIDS remains a major public health problem, as over 40 million people worldwide are infected and new infections continue at greater than 2 million/year. 1 Combination antiretroviral therapy (cART) effectively controls ongoing viral replication and can restore lost numbers of CD4+ T-cells. However, treatment fails to eliminate virus from latently infected cells. 2 In subsets of resting CD4+ memory T-cells, integrated proviral DNA persists and can be reactivated to produce replication-competent virus. This can result in rapid viral rebound when combination antiretroviral therapy ceases. 3, 4 Therefore, those infected must maintain life-long treatment due to viral persistence in cell reservoirs.
Elimination of latent proviral DNA remains enigmatic. During latency, HIV-1-infected cells produce little or no viral proteins, thereby avoiding host antiviral immune clearance or direct viral cytopathicity. Eradication of virus requires its clearance and prevention of re-infection of latently infected cell CD4+ T effector memory cells 5, 6 among other infected lymphocytes and monocyte-macrophages present in the spleen, lymph nodes, brain, genitourinary tract and gut to achieve a disease 'cure'. 7 Recently, gene editing techniques were developed and based on RNAguided Cas9 (known as CRISPR/Cas9) to specifically target the HIV-1 genome and eliminate integrated copies of the proviral DNA. We identified several specific sequences within the U3 region of the HIV-1 long-term repeat (LTR) that serve as targets for the creation of specific guide RNAs (gRNAs) to edit their target sequences by single and multiplex Cas9/gRNAs complexes.
This strategy can lead to complete elimination of viral replication in latently infected CD4+ T-cells and mononuclear phagocytes (monocyte, macrophages, microglia and dendritic cells). 8, 9 Our CRISPR/Cas9 had no genotoxic effects or off-target editing of the host genome, and for the first time, showed the ability of this technology to precisely excise a 9709 bp DNA fragment of the integrated proviral genome that spans the 5′ and 3′ HIV-1 LTRs. The presence of multiplex gRNAs and Cas9 also protects against subsequent HIV-1 infection and was used successfully in cell models of human disease. [10] [11] [12] All of these observations offer a novel pathway for the use of CRISPR/Cas9 as a strategy to permanently remove HIV-1 DNA from the host and to develop a potential means to cure HIV/AIDS.
However, an important challenge relates to the in vivo delivery of functional CRISPR/Cas9 to tissues and cells that harbor viral DNA. In recent years, Adeno-Associated Virus Vectors (AAV) has captured much attention as a gene delivery system for treating human disease caused by a gene loss or mutation. 13 The advantages of the AAV delivery scheme include its low toxicity and sustained gene expression, which can extend to 12 months after a single administration. 14, 15 The most common diseases targeted by AAV delivery systems include cancer, heart failure, neurodegenerative diseases, arthritis, muscular dystrophy, cystic fibrosis and Canavan's disease among others. 13, 16, 17 In this concise study we present results from our preliminary studies in two small animal species in which AAV serotype 9 was used as a delivery platform to bring HIV-1-targeted CRISPR/Cas9 to various cells and organs of two species of small animals for excising the integrated 1 copies of HIV-1 from the host genome to edit integrated HIV-1 DNA as a strategy towards viral elimination in two species of small animals.
RESULTS
As a testing platform, first we used HIV-1 Tg26 transgenic mice, which carry a transgene derived from the genome of HIV-1 NL4-3 with a deletion of a 3.1 kb spanning the C-terminal of the Gag and the N-terminal of the Pol genes (Figure 1a) . Although no productive HIV-1 replication is reported, expressions of viral transcripts, at low levels, have been detected in various tissues before disease onset. [18] [19] [20] Select clinical features of HIV-1 infection and AIDS including HIV-associated nephropathy are seen. 21, 22 Owing to the early lethality of the mice, we crossed Tg26 mice into the C57BL/6L background to create animals where secondary disease is limited and mice can survive to 12 months of age. For delivery of genes expressing Cas9 and gRNAs, we selected an AAV 9 vector. One of the major challenges associated with the use of AAV vectors relates to its genome accepting capacity. To alleviate this problem, we selected a smaller Cas9 or homolog, saCas9 (124 kDa), derived from Staphylococcus aureus that can edit the genome with efficiency similar to that of the original Cas9 from Streptococcus pyrogens (spCas9), although being more than 1 kb shorter. 23 The gene encoding saCas9 along with DNA sequences corresponding to the two gRNAs for targeting the HIV-1 LTR (gRNA LTR 1) and the Gag gene (gRNA Gag D)
were cloned into the all-in-one AAV 9 vector DNA. Figure 1a illustrates the structural organization of the HIV-1 genome highlighting the region of the viral gene that was deleted for creating the transgene in Tg26 mice and the position of gRNA LTR 1 and gRNA Gag D. As a first step, we performed ex vivo studies by developing a culture of mouse embryo fibroblasts (MEFs) from Tg26 animals and using them to assess the ability of the recombinant AAV 9 (rAAV 9 ) containing saCas9/gRNAs, rAAV 9 : saCas9/gRNAs, in excising portions of integrated HIV-1 DNA. Figure 1b illustrates results from PCR gene amplification utilizing a pair of primers (P1 and P2) spanning − 413/ − 391 for the LTR and +888/+910 for the Gag gene ( Figure 1a ). In addition to the expected full-length amplicon of 1323 bp, a smaller fragment of 345 bp was detected in rAAV 9 -treated cells. These were not seen in control untreated cells. Results from sequencing data verified excision of a 978 bp DNA fragment spanning the two guide RNAs and re-joining the residual viral DNA after excision (as schematized in Figure 1a ). For in vivo studies, we selected two Tg26 animals and two age-matched (2 months) control mice for tailvein injections of 10 12 genomic copies (GC) of rAAV 9 :saCas9/gRNA. After 5 days, the injections were repeated and 5 days later the animals were sacrificed and the liver, heart, spleen, lung, kidney, brain and blood lymphocytes were collected ( Figure 2a ). In a first pass experiment DNA from liver was analyzed by PCR amplification using P1 and P2 primers. Consistent with the results from MEF cell culture, results of gel analysis of PCR products showed a full-length (1323 bp) and a truncated (345 bp) DNA fragment after amplification Results from DNA sequencing of the 160 bp DNA verified excision of the 978 bp DNA sequence spanning between gRNA LTR 1 and gRNA Gag D (Figure 2c ). We next assessed the effect of rAAV 9 : saCas9/gRNA on HIV-1 DNA in other tissues. As seen in Figure 2d , a distinct 160 bp DNA fragment, indicative of excision of the HIV-1 DNA between the LTR and Gag genes by gRNAs LTR1 and gRNAs Gag D, as verified by DNA sequencing, was observed in all tissues of rAAV 9 :saCas9/gRNA treated animals (lane 2). These were not observed in control untreated animals (lane 1). The 160 bp amplicon produced on treatment of MEFs with rAAV 9 served as an additional control (lane 3). In parallel studies, we assessed the effect of our excision strategy in another small animal model, that is, rat, which encompasses the identical transgene used for the development of the mouse model. Here, we employed a retroorbital route of inoculation of rAAV 9 . Thirty-day old rats injected twice with 2.73 × 10 12 of rAAV 9 :saCas9/gRNA at 5 day intervals led to the excision of segments of HIV-1 DNA spanning the 5′-LTR and 2) and MEFs (lane 3) demonstrating the absence of the 160 bp-truncated DNA fragment in animals with no inoculation of rAAV 9 :saCas9/gRNAs and the detection of this band in the animals and cells that received rAAV 9 :saCas9/ gRNAs.
In vivo excision of HIV-1 DNA by gene editingthe Gag gene from circulating lymphocytes, as examined by direct sequencing of the amplicon that was generated by target specific PCR. As illustrated in Figure 3 , a detailed analysis of the sequencing data from several PCR products of the excised fragments and their alignment with the reference HIV-1 DNA verified excision of the viral DNA with some variations in tissues from animals treated with rAAV 9 :saCas9/gRNA. We also examined the level of viral gene expression by measuring the levels of Gag and Env transcripts using quantitative RT-PCR. As seen in Figure 3 , the level of viral RNA was drastically decreased in circulating blood cells obtained from animals treated with rAAV 9 : Cas9/gRNA, indicating that excision of the viral genome has a significant impact on the level of viral gene expression from the integrated copies of HIV-1 DNA. Examination of viral RNAs in lymph nodes also showed suppression of viral RNAs in the treated rats (data not shown).
DISCUSSION
In recent years, methodologies have been developed that are specifically able to target nucleotide sequences within precise regions of DNA and represent a remarkable addition to the armamentarium for genetic manipulation. 24 Perhaps the best such methodology is the clustered regulatory interspaced short palindromic repeat (CRISPR)-associated 9 (Cas9) system, which is specific, effective, versatile and provides unprecedented control over genome editing for a variety of purposes, for example, correction of inborn genetic errors 25 and genetic approaches to use against human viruses 26 and cancers. 27 Crucially, application of CRISPR/Cas9 to the clinic will require a method of safe and efficient delivery in vivo. A promising possibility is to use AAV, which is only mildly immunogenic, but is a small virus unable to fit the 4.1 kb spCas9 gene. One solution is to use proteins with a similar function but smaller size such as Cas9 form Staphylococcus aureus (saCas9), which has a similar efficiency although being more than 1 kb shorter. 27 In this communication, we demonstrate that the AAV 9 -based saCas9/gRNA gene editing delivery system can excise a segment of integrated copies of the HIV-1 genome in transgenic mice and rats carrying HIV-1 DNA sequences. Further, our results demonstrate suppression of viral RNA production in the animals that were treated with the therapeutic rAAV and exhibit excision in the designated segments of the viral genome by saCas9/gRNAs in blood and lymph nodes. These findings are an important advance from earlier cell culture work demonstrating CRISPR/Cas9 excision of viral infection from latently infected cells, in vitro 8, 9 or Figure 3 . Elimination of segments of the integrated HIV-1 DNA from rat blood cells after inoculation with rAAV 9 :saCas9/gRNA and expression of viral RNAs. (a) Total DNA from circulating lymphocytes of the control (untreated) and experimental (treated with rAAV 9 :saCas9/gRNA) rats was prepared and used for PCR amplification using a set of primers derived from the 5′-LTR and Gag gene (shown in Materials and methods). After gel electrophoresis, a short DNA fragment of~198 bp was detected in the treated, but not the control samples, which were then purified and cloned in a TA vector. Several clones were selected for DNA sequencing. Four representative DNA sequences (C1-C4) obtained from each animal were aligned to the reference LTR-Gag region of the HIV-1 pNL 4-1 sequence. The positions and nucleotide composition of LTR 1 and Gag D target sequences are highlighted in green, PAM in red and LTR specific primers using PCR are highlighted in blue. (b) Total RNA prepared from circulating lymphocytes and lymph nodes of transgenic rats, control (untreated) and treated with rAAV 9 :saCas9/gRNA for 10 days were prepared and used for quantitative RT-PCR for detection of Gag RNA and Env RNA. Expression of β-actin in each assay was determined and the values were used as reference for quantification of viral RNA expression.
In vivo excision of HIV-1 DNA by gene editing R Kaminski et al suppression of ongoing HIV-1 replication, ex vivo. 28 The work is a step forward towards the utilization of CRISPR/Cas9 platform technology as a robust HIV-1 gene elimination strategy in an in vivo setting. In principle, this technology can be further refined and used in tandem with an antiretroviral regimen to enhance the efficacy of editing and as such lead to a similar favorable outcome in infected animals and inevitably in humans. The ease of AAV delivery for the CRISPR/Cas9 technology and the flexibility of CRISPR/Cas9 in developing new gRNAs for targeting DNA sequences of HIV-1 with minor nucleotide variations bring additional values to this therapeutic platform for personalizing the cure strategy, if deemed appropriate.
MATERIALS AND METHODS
Construction of the AAV 9 delivery vector The background plasmid for creating the AAV delivery system, px601-AAV-CMV::NLS-saCas9-NLS-3xHA-bGHpA;U6::Bsa1-SgRNA (briefly, pX601) was a gift from Feng Zhang (Addgene #61591). 23 The oligonucleotide encompassing the DNA sequences corresponding to the LTR and Gag targets were cloned ahead of the U6 promoter at the Bsa1 site in pX601. After confirmation by sequencing, 20 ng of pX601 saCas9 gRNA HIV-1 LTR1/Gag D plasmid was provided to the Penn Vector Core, Gene Therapy Program (Perelman School of Medicine, University of Pennsylvania) for plasmid DNA production, DNA structure/sequence analysis, packaging in AAV serotype and high titer production.
Mouse embryo fibroblasts (MEFs) HIV-1 Tg26 MEFs were prepared from 17-day-gestation embryos by mechanical and enzymatic dissociation and maintained in Dulbecco's Modified Eagle's Medium supplemented with 10% fetal bovine serum. MEF cells were prepared as previously described 29 and genotyped by PCR using primers specific for the HIV transgene. 19, 22 In vitro transduction of Tg26 MEF Tg26 MEF cells were transduced with AAV-CRISPR/Cas9 at MOI 10 5 and 10
6
. Viral inoculum was prepared in Opti-Mem, cells were incubated with the virus for 1 hour in minimal volume (0.5 ml well − 1 in a 6-well-plate) then 1 ml of growth medium was added and left overnight. The next day, inoculum was removed, cells were washed with PBS and fed fresh growth medium. Cells were collected for DNA analysis 1 week after transduction.
In vivo rAAV 9 :saCas9/gRNA administration For studies with transgenic mice, 100 μl of AAV 9 : Cas9/gRNA (2.73 × 10 12 ) or 100 μl of PBS for control animals was injected via tail vein into mice at day 0 and day 5. At day 5, one pair (AAV and PBS) animals were subjected to a retro-orbital bleed for a blood sample, killed and tissues collected. The second pair of animals received a second tail-vein injection of AAV-Cas9 or PBS, and was killed for collection of tissue 7 days later after retro-orbital bleed. Tissues collected were brain, heart, lung, liver, kidney, spleen and peripheral blood for lymphocyte recovery. For studies with rats, we followed a similar approach as described above and the tissues were collected ten days after the initial injection for DNA and RNA analysis.
DNA analysis Genomic DNA was isolated from cells/tissues using NucleoSpin Tissue kit (Macherey-Nagel, Duren, Germany) according to the manufacturer's protocol. Overall 25 ng of genomic DNA was subjected to PCR using Terra PCR direct polymerase mix (Takara, Shiga, Japan; Clontech, Mountain View, CA, USA) under the following PCR conditions: 98°C for 3 min, 35 cycles (98°C for 10 s, 68°C for 1.30 min), 68°C for 5 min and resolved in 1% agarose gel. Nested PCRs were performed under the same conditions using 5 μl of first PCR reaction. PCR using genomic DNA extracted from Tg26 rat blood samples was performed in one step using LTR F and nested-Gag R primers. PCR products were purified, cloned into TA vector (Invitrogen, Carlsbad, CA, USA) and sent for Sanger sequencing (Genewiz, South Plainfield, NJ, USA) and aligned in Clustal Omega (EMBL-EBI) software (Cambridgeshire, UK) using HIV-1 NL 4-3 sequence as a reference.
RNA analysis Total RNA was prepared from tissues using TRIzol reagent (Ambion, Foster City, CA, USA) according to manufacturer's protocol followed by DNAse I treatment and RNA cleanup using RNeasy Mini Prep Kit (Qiagen, Hilden, Germany). Next 1 μg of RNA was used for M-MLV reverse transcription reactions (Invitrogen). cDNA was diluted and quantified using TaqMan qPCR specific for HIV-1 Gag and Env genes and cellular rat beta-actin gene as a reference (for primers see Table 1 ). qPCR conditions: 98°C 5 min, 45 cycles (98°C 5 min, 45 cycles (98°C 15 s, 62°C 30 s with acquisition, 72°C 1 min). Reactions were carried out and data analyzed in a LightCycler480 (Roche, Basel, Switzerland) using relative quantification mode. In vivo excision of HIV-1 DNA by gene editing
